Nanobiotix's Nanoparticle Technology Shows Tumor-Killing Effect in Early-Stage Head & Neck Cancer

Nanobiotix NBTX, ahead of the 2021 Annual Meeting of the American Society for Clinical Oncology meeting, has said that its nanoparticles were able to shrink tumors in about 77% of patients in a small Phase 1 trial.
NBTXR3 consists of crystalline nanoparticles that are delivered by intratumoral injections.
Of 13 evaluable patients given NBTXR3 in combination with anti-PD-1 therapy, just under 77% saw tumor regression.
The open-label Phase I trial dubbed Study 1100 enrolled patients who hadn’t previously received a checkpoint inhibitor and patients who showed prior resistance to one.
Of the five patients who hadn’t received an anti-PD-1 therapy, 80% saw tumor regression, and 60% saw an objective response. That included one complete response, he added.
Of the eight patients who showed prior resistance to an anti-PD-1, 75% saw tumor regression, and 50% had objective responses, including one complete response and two partial responses.
NBTXR3 is already approved for locally advanced soft tissue sarcoma in 27 EU countries. Still, Nanobiotix is looking to first bring it to the U.S. as a single agent for head and neck squamous cell carcinoma (HNSCC).
Then it’ll pursue an OK in combination with anti-PD-1 therapy.
Price Action: NBTX shares are up 7.07% at $17.51 on the last check Friday.